Determine the enzymatic kinetic characteristics of CYP3A4 variants utilizing artemether-lumefantrineArticle Published on 2023-11-302024-09-10 Journal: Food Chem Toxicol [Category] 말라리아, [키워드] Artemether CYP3A4 gene polymorphism Lumefantrine UPLC-MS/MS. PMC 바로가기
Clinically Relevant Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Antiseizure Medications: Implications for the Management of COVID-19 in Patients with EpilepsyArticle Published on 2022-09-012022-11-15 Journal: Clinical pharmacokinetics [Category] COVID19(2023년), SARS, 진단, 치료제, [키워드] administration anti-SARS-CoV-2 Antiviral bidirectional boost Clinical efficacy clinically complicate Concentration Concomitant concomitant treatment country COVID-19 CYP3A4 dosing interval drug-drug interaction Efficacy European Evidence high risk information inhibitor intravenous involved medication molnupiravir Nirmatrelvir Patient patients treated persistence plasma plasma concentration Remdesivir Ritonavir severe COVID-19 disease subject substrates the SARS-CoV-2 virus Toxicity Treatment [DOI] 10.1007/s40262-022-01152-z PMC 바로가기
Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences위험, 약리학 그룹 및 결과에 따라 분류된 Paxlovid 팩트 시트에 나열된 상호 작용Article Published on 2022-08-012022-09-11 Journal: Revista española de quimioterapia : publicación [Category] COVID19(2023년), SARS, 치료제, [키워드] Administered Antiviral consequence COVID-19 CYP3A4 drug Drug interactions ELLA English force groups inhibitor Isoenzyme low dose medication Medicine Medicines metabolism Nirmatrelvir oxidative Paxlovid pharmacological Precaution precautions Prophylaxis protease responsible Ritonavir SARS-CoV-2 SARS-CoV-2 main protease Spanish therapeutic therapeutic effect Treatment [DOI] 10.37201/req/054.2022 PMC 바로가기 [Article Type] Article
In vitro characterization of the furin inhibitor MI-1851: Albumin binding, interaction with cytochrome P450 enzymes and cytotoxicityArticle Published on 2022-07-012023-07-09 Journal: Biomedicine & pharmacotherapy = Biomédecine & phar [Category] COVID19(2023년), [키워드] cell viability CYP3A4 furin inhibitor Human serum albumin MI-1851 primary human hepatocytes [DOI] 10.1016/j.biopha.2022.113124 PMC 바로가기
A rare case of drug-induced bradycardia associated with the just low dose use of methylprednisolone in a child with COVID-19COVID-19에 걸린 아동에서 메틸프레드니솔론의 저용량 사용과 관련된 약물 유발성 서맥의 드문 사례Case Reports Published on 2022-04-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 치료제, [키워드] Affect aggravate Arbidol bradycardia Child competitive inhibition coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 CYP3A4 enzyme Infection Inflammation low dose Methylprednisolone Occurrence premise reduce Side effect Side effects the patient tissue damage Treatment with COVID-19 [DOI] 10.1002/jmv.27525 PMC 바로가기 [Article Type] Case Reports
Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIVDexamethasone은 약물-약물 상호작용의 용량 의존적 가해자입니다.Article Published on 2022-02-232022-09-11 Journal: Journal of Antimicrobial Chemotherapy [Category] COVID19(2023년), SARS, 치료제, [키워드] antiretroviral ARV assessment complex Course COVID-19 patient CYP3A4 cytochrome P450 daily dose Dexamethasone dosage dose-dependent drug-drug interaction drugs evaluated implication in vitro in vivo inducer inhibitor inhibitors Interaction management P450 recommendation substrate substrates Treatment victim with HIV [DOI] 10.1093/jac/dkab412 PMC 바로가기 [Article Type] Article
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialCovid-19 (회복)로 병원에 입원 한 환자의 콜히친 : 무작위, 통제, 오픈 라벨, 플랫폼 시험Randomized Controlled Trial Published on 2021-12-012022-08-13 Journal: The Lancet. Respiratory Medicine [Category] MERS, SARS, 임상, [키워드] (Medical Research Council) 1:1 28-day mortality allocation concealment Analysis anti-inflammatory actions assigned baseline both groups by mouth clinically suspected clinician Colchicine colchicine 1 mg colchicine group composite endpoint CYP3A4 CYP3A4 inhibitor death died Diltiazem discharge discharged Efficacy and safety eligible enrolled estimated glomerular filtration rate evaluate filtration rate finding followed by for inclusion Frequency funding glomerular filtration rate had no hospital Hospital stay hospitalised hospitals in Indonesia hospitals in Nepal in both groups Indonesia Innovation Intention intention-to-treat Invasive mechanical ventilation ISRCTN Laboratory less medical history Medical Research Council moderate nasogastric tube Nepal no significant difference Open-label open-label trial opinion participant Patient Platform trial Primary outcome proportion randomisation randomised Randomly rate ratio receive receiving RECOVERY trial reductions reductions in Registered risk risk ratio SARS-COV-2 infection secondary endpoint Secondary endpoints significant difference Standard of care subgroups of patients the patient Treatment treatment for COVID-19 Trial twice a day usual care usual care group web-based simple Wellcome Trust with COVID-19 [DOI] 10.1016/S2213-2600(21)00435-5 PMC 바로가기 [Article Type] Randomized Controlled Trial
Herb-Drug Interaction Between Xiyanping Injection and Lopinavir/Ritonavir, Two Agents Used in COVID-19 PharmacotherapyPharmacology Published on 2021-11-112022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] administration Affect agent approach AUC benefit changed clinical setting clinician Combination coronavirus disease Coronavirus disease 2019 COVID-19 CYP3A4 death decrease demonstrated dose drugs effective Epidemic exhibit exhibited expression herb-drug interactions human liver in vitro in vivo inhibited inhibiting injection Interaction intravenous dose lack Lopinavir/ritonavir LPV outbreak parameter Patient pharmacokinetic pharmacotherapy Precaution Protein risk RTV Seven significantly TCM Traditional Chinese medicine Treatment xiyanping injection [DOI] 10.3389/fphar.2021.773126 PMC 바로가기 [Article Type] Pharmacology
Pharmacogenomic landscape of COVID-19 therapies from Indian population genomes인도 인구 게놈에서 코로나19 치료제의 약리유전체학적 풍경Article Published on 2021-07-012022-09-11 Journal: Pharmacogenomics [Category] SARS, 변종, 유전자 메커니즘, 치료제, [키워드] ABCB1 ALB analyzed candidate clinical decision clinically COVID-19 COVID-19 therapeutics covid-19 therapies COVID-19 therapy COVID-19 treatment CYP3A4 Deleterious drug drug-drug interaction Drug–drug interactions drug–drug–gene interactions drugs Evidence Genome Indian population individual inhibitor Interaction material metabolic disorder Numerous overlapped Patient pharmacogenetic pharmacogenomics pharmacogenomics. populations predicted therapy Treatment validation study variant variants whole genome whole genomes with COVID-19 [DOI] 10.2217/pgs-2021-0028 PMC 바로가기 [Article Type] Article
Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients로피나비르/리토나비르 및 하이드록시클로로퀸을 사용한 치료는 COVID-19 환자의 급성 신장 손상과 관련이 있습니다Research Article Published on 2021-05-112022-09-10 Journal: PLoS ONE [Category] SARS, 치료제, [키워드] Acute kidney injury acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Affect AKI Analysis analyzed Antiviral agents both groups Care control group controls coronavirus coronavirus disease correlation COVID-19 COVID-19 patient COVID-19 patients creatinine CYP3A4 cytochrome P450 enzyme Germany Hospitalized Hydroxychloroquine ICU ICU patient ICU Patients in both group in vitro activity incidence increase in independent risk factor Interaction Kidney function Kidney injury linear linear correlation Lopinavir Lopinavir/ritonavir mechanism Mortality National Early Warning Score NEWS non-ICU non-ICU patients P450 Patient patients R 2 receiving respiratory Result Ritonavir SARS-CoV-2 score serum creatinine severe acute respiratory syndrome Coronavirus severely ill COVID-19 patients severity severity of illness Standard therapy therapy treated Treatment treatment of COVID-19 university university hospital was performed with COVID-19 [DOI] 10.1371/journal.pone.0249760 PMC 바로가기 [Article Type] Research Article